Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Molecular and Technological Advances in the Diagnosis and Drug Therapies...
share announcement

Molecular and Technological Advances in the Diagnosis and Drug Therapies of Atherosclerotic Cardiovascular Diseases (ASCVDs)

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Molecular Targeted Therapy".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 813

Special Issue Editor

Dr. Nikolaos Kadoglou

E-Mail Website
Guest Editor
Medical School, University of Cyprus, Nicosia CY2024, Cyprus
Interests: atherosclerotic cardiovascular diseases; biomarkers; atherosclerotic plaque vulnerability; molecular therapies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Atherosclerotic cardiovascular diseases (ASCVDs) are the leading cause of morbidity and mortality in the Western world. The escalating global prevalence of ASCVDs necessitates modern advancements in molecular diagnostics and technology. Primary prevention strategies should prioritize the early identification of atherosclerosis. This is a very demanding process involving genetic, biochemical, pathophysiological and cardiovascular imaging studies, which will enable personalized treatment approaches. Similarly, secondary prevention of ASCVDs should follow with the principles of precision medicine determining the extent of follow-up and the intensity of therapy. Multiple and complex pathophysiologic mechanisms are involved in atherosclerosis progression. Hence, there is still an increasing need to develop and apply more personalized diagnostic tests (molecular and imaging) and therapeutic regimens for ASCVDs. We invite the submission of research and narrative reviews focusing on basic atherosclerosis studies to advance prevention, diagnosis, risk assessment, and treatment through personalized medicine. This Special Issue aims to acquaint medical professionals and researchers with recent advances in ASCVDs within the context of personalized medicine. Original research and reviews are encouraged for this Special Issue. 

Topics include, but are not confined to the following:

  • Experimental atherosclerosis research;
  • Novel biomarkers in ASCVDs;
  • Genomics, GWAS, and population genetics;
  • Atherosclerosis epigenetics and microRNAs;
  • Lipids, lipoproteins, and apolipoproteins;
  • Proteomic and metabolomic exploration of atherosclerosis;
  • Inflammation and/or immunology within atherosclerotic lesions;
  • Arterial expansive and constrictive remodeling;
  • Advances in cardiovascular imaging;
  • Oxidative stress influence;
  • Arterial calcification;
  • Medications stabilizing atherosclerotic plaques. 

Dr. Nikolaos Kadoglou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atherosclerosis
  • personalized medicine
  • molecular diagnostics
  • biomarkers
  • cardiovascular imaging
  • atherosclerotic cardiovascular diseases
  • basic research
  • gene therapy
  • precision medicine for diagnosis and treatment

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 3829 KiB  
Article
The Prognostic Role of Global Longitudinal Strain and NT-proBNP in Heart Failure Patients Receiving Cardiac Resynchronization Therapy
by Nikolaos P. E. Kadoglou, Sjoerd Bouwmeester, Anouk G. W. de Lepper, Marloes C. de Kleijn, Ingeborg H. F. Herold, Arthur R. A. Bouwman, Ioannis Korakianitis, Tim Simmers, Franke A. L. E. Bracke and Patrick Houthuizen
J. Pers. Med. 2024, 14(2), 188; https://doi.org/10.3390/jpm14020188 - 08 Feb 2024
Viewed by 632
Abstract
Background: We aimed to evaluate whether baseline GLS (global longitudinal strain), NT-proBNP, and changes in these after cardiac resynchronization therapy (CRT) can predict long-term clinical outcomes and the echocardiographic-based response to CRT (defined by 15% relative reduction in left ventricular end-systolic volume). Methods: [...] Read more.
Background: We aimed to evaluate whether baseline GLS (global longitudinal strain), NT-proBNP, and changes in these after cardiac resynchronization therapy (CRT) can predict long-term clinical outcomes and the echocardiographic-based response to CRT (defined by 15% relative reduction in left ventricular end-systolic volume). Methods: We enrolled 143 patients with stable ischemic heart failure (HF) undergoing CRT-D implantation. NT-proBNP and echocardiography were obtained before and 6 months after. The patients were followed up (median: 58 months) for HF-related deaths and/or HF hospitalizations (primary endpoint) or HF-related deaths (secondary endpoint). Results: A total of 84 patients achieved the primary and 53 the secondary endpoint, while 104 patients were considered CRT responders and 39 non-responders. At baseline, event-free patients had higher absolute GLS values (p < 0.001) and lower NT-proBNP serum levels (p < 0001) than those achieving the primary endpoint. A similar pattern was observed in favor of CRT responders vs. non-responders. On Cox regression analysis, baseline absolute GLS value (HR = 0.77; 95% CI, 0.51–1.91; p = 0.002) was beneficially associated with lower primary endpoint incidence, while baseline NT-proBNP levels (HR = 1.55; 95% CI, 1.43–2.01; p = 0.002) and diabetes presence (HR = 1.27; 95% CI, 1.12–1.98; p = 0.003) were related to higher primary endpoint incidence. Conclusions: In HF patients undergoing CRT-D, baseline GLS and NT-proBNP concentrations may serve as prognostic factors, while they may predict the echocardiographic-based response to CRT. Full article
(This article belongs to the Special Issue Molecular and Technological Advances in the Diagnosis and Drug Therapies of Atherosclerotic Cardiovascular Diseases (ASCVDs))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop